Discover
SCYX
SCYNEXIS, Inc.
4.23
2 x 3.17
2 x 5.27
bid
ask
+
0.16
3.93%
2 @ 04:00 PM
4.23 +0.00 (0.00%)
| Ytd | -16.40% | |
| 1y | -24.60% |
4.07
day range
4.46
3.68
52 week range
10.48
| Open | 4.09 | Prev Close | 4.07 | Low | 4.07 | High | 4.46 | Mkt Cap | 42.01M |
| Vol | 115.57K | Avg Vol | 62.17K | EPS | -3.84 | P/E | N/A | Forward P/E | 6.80 |
| Beta | 1.50 | Short Ratio | 5.04 | Inst. Own | 44.31% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 05-11 | 50-d Avg | 5.70 | 200-d Avg | 6.08 | 1yr Est | 6.67 |
SCYX News
benzinga.com
SCYNEXIS Starts Phase 1 Trial Of SCY-770 Activator Of Two Dosing Regimens
SCYNEXIS, Inc. (NASDAQ: SCYX), a clinical-stage biotechnology company advancing novel therapies for
globenewswire.com
SCYNEXIS Initiates Phase 1 Study of SCY-770, a Novel AMPK Activator for the Treatment of Autosomal D
JERSEY CITY, N.J., June 30, 2026 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX), a clinical-stage